| Gene symbol | TP53 | Synonyms | BCC7, BMFS5, LFS1, P53, TRP53 | Type of gene | protein-coding |
| Chromosome | 17 | Map location | 17p13.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | tumor protein p53 | ||||
| GTO ID | GTC0434 |
| Trial ID | NCT03510897 |
| Disease | Cardiac Surgery |
| Altered gene | P53 |
| Therapeutic/Target gene | Target gene |
| Therapy | siRNA |
| Treatment | I5NP|QPI-1002|teprasiran |
| Phase | Phase3 |
| Recruitment status | Terminated |
| Title | A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of QPI-1002 for the Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for Acute Kidney Injury (AKI) Following Cardiac Surgery |
| Year | 2018 |
| Country | Australia|Austria|Belgium|Canada|Czechia|France|Germany|NewZealand|Spain|UnitedKingdom|UnitedStates |
| Company sponsor | Quark Pharmaceuticals |
| Other ID(s) | QRK309 |
| Cohort1: QPI-1002 | |||||||||||||
|
|||||||||||||
| Cohort2: Placebo | |||||||||||||
|
|||||||||||||